This study is testing a new oral capsule called JBZ-001 for people with advanced solid tumors (cancers that form solid masses) or hematological (blood) cancers that have come back or are not responding to standard treatments. The main goals are to see how safe JBZ-001 is, what side effects it might cause, and to find the highest dose that can be given safely. Researchers will also look at how the drug works in the body and if it shows any early signs of helping to treat the cancer. JBZ-001 is a type of drug called a checkpoint inhibitor. You may be able to join if you are 18 or older and have a solid tumor that has relapsed or is refractory (not responding to treatment), and for which standard treatments are not available or tolerated. The study is currently recruiting about 25 participants.

Study design

This is a Phase 1, open-label study, meaning both you and the study team will know which treatment you are receiving. It will involve a small number of participants, starting with 3 to 6 people at each dose level to find the safest and most effective dose.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The main safety and dose evaluations will be measured over 28 days. If you experience a benefit, you may continue treatment until your disease progresses or side effects become too severe.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.